Autolus Therapeutics Presents Clinical Data Updates at the European Hematology Association Congress - AUTO4 shows high level of clinical activity with a novel targeting approach for patients with T Cell Lymphoma- AUTO1/22 demonstrates encouraging and durable responses in children ineligible for...

Autolus to hold Annual General Meeting (AGM) of Shareholders on Tuesday, June 28, 2022 LONDON, May 31, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today posted...

Autolus Therapeutics to Participate in the Jefferies Healthcare Conference, being held in New York from June 8 – 10, 2022 LONDON, May 27, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces...